이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MorphoSys 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Arkadius Pichota

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	6.5yrs

최근 관리 업데이트

Recent updates

CEO

Arkadius Pichota

less than a year

테뉴어

Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	4.5yrs	€1.10m	0.0036% € 97.9k
Arkadius Pichota	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Lukas Gilgen	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Tim Demuth	Chief Research & Development Officer	1.8yrs	데이터 없음	데이터 없음
Klaus De Wall	Head of Accounting & Tax	no data	데이터 없음	데이터 없음
Margit Urban	Head of Discovery Alliances & Technologies	no data	데이터 없음	데이터 없음
Julia Neugebauer	Head of Investor Relations	no data	데이터 없음	데이터 없음
Barbara Krebs-Pohl	Chief Business Officer	no data	데이터 없음	데이터 없음
Günter Wellnhofer	Head of Technical Operations	no data	데이터 없음	데이터 없음
Harald Watzka	Head of Alliance Management	no data	데이터 없음	데이터 없음
Yen Ching Chua	Head of Clinical Operations	no data	데이터 없음	데이터 없음
Kathrin Tissot	Head of Business Team	no data	데이터 없음	데이터 없음

0.9yrs

평균 재임 기간

경험이 풍부한 관리: MOR 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bruce Cheson	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Gunther Adolf	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Sergio Quezada	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Raymond Sweet	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Sharon Curran	Independent Member of Supervisory Board	5.1yrs	€92.60k	데이터 없음
Heinrich V. Moisa	Chairman of the Supervisory Board	less than a year	데이터 없음	데이터 없음
Silke Mainka	Member of the Supervisory Board	less than a year	데이터 없음	데이터 없음
Romain Lege	Deputy Chairman of the Supervisory Board	less than a year	데이터 없음	데이터 없음

6.5yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: MOR 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

MorphoSys 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

MorphoSys AG Announces Board Changes

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

MorphoSys AG Announces Executive Changes

MorphoSys AG Announces Supervisory Board Changes

MorphoSys AG Announces Management Changes

MorphoSys AG, Annual General Meeting, May 19, 2021

Recent updates

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

MorphoSys: Hold Rating Until The Novartis Deal Closes

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis And MorphoSys Are A Perfect Match

Novartis Reportedly in Lead to Acquire MorphoSys

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

MorphoSys May Not Recover From Adventurous Constellation Buyout

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte and MorphoSys presents new three-year data for blood cancer therapy

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

MorphoSys reports Q1 results

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

MorphoSys AG Announces Management Changes

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Morphosys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

MorphoSys AG, Annual General Meeting, May 19, 2021

Incyte and MorphoSys AG Announces Data Evaluating Tafasitamab with and Without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented At ASH 2020

MorphoSys AG (MOR) Investor Presentation - Slideshow

Morphosys' Licensee Announces Approval by the European Commission for Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

MorphoSys Appoints Thomas Biegi as Vice President, Head of Corporate Communications

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

MorphoSys reports Q3 results

MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition

MorphoSys AG Raises Financial Guidance for the Financial Year 2020

Jens Holstein Decides to Step Down as Member of the Morphosys AG's Management Board, Effective December 31, 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령